La Jolla Pharmaceutical Co. (Nasdaq: LJPC) reported that the U.S. Patent and Trademark Office issued a notice of allowance for its patent application covering methods of treating chronic inflammation by using modified pectin.
Specifically, the patent, which expires in 2025 without taking into account patent term extension, provides proprietary protection for methods of treating chronic inflammation by administration of modified pectin with a molecular weight greater than 25 kilodaltons.
“Chronic inflammation is the principal underlying cause of fibrosis in multiple chronic ailments such as kidney, liver, heart and lung disease,” said James Rolke, senior director of research and development at La Jolla and an inventor on the allowed patent application. “These newly allowed claims solidify our proprietary position for using modified pectin as a treatment for organ disease that results from chronic inflammation.”
Chronic inflammation is the hallmark of many serious, debilitating and prevalent conditions such as non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD). The company’s lead product candidate, GCS-100, which is covered by this issued patent, is being studied in a randomized, placebo-controlled Phase 2 clinical study in patients with CDK. Data on the primary efficacy endpoint from this study is due to be released in March of this year.